Main Category: Prostate / Prostate Cancer
Also Included In: Radiology / Nuclear Medicine
Article Date: 07 Mar 2013 – 0:00 PST
email to a friend printer friendly opinions
<!– rate article
Patient / Public:
3 (1 votes)
Healthcare Prof:
5 (1 votes)
Two novel radiolabeled small molecules targeting prostate-specific membrane antigen (PSMA) have excellent potential for further development as diagnostic and therapeutic radiopharmaceuticals, according to research published this month in The Journal of Nuclear Medicine. The imaging agents -123I-MIP-1072 and 123I-MIP-1095 – were shown to have a high sensitivity of lesion detection in bone, soft tissue and the prostate gland with minimal retention in non-target tissue.
An estimated 238,500 men will be diagnosed with prostate cancer in 2013, and 29,700 will die from the disease. Accurate diagnosis and staging of prostate cancer is critical to determining appropriate patient management. Patients with localized disease may benefit from a curative treatment, while those with bone metastases are typically treated with systemic therapy.
“Current imaging techniques have limitations in diagnosing and staging prostate cancer. New imaging approaches, including the radiolabeled small molecules 123I-MIP-1072 and 123I-MIP-1095, may assess disease status more accurately,” said John J. Babich, PhD, lead author of the article “First-in-Man Evaluation of Two High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer.” Babich continued, “Improved imaging approaches could better facilitate the selection of optimal treatment and improve patient outcomes.”
Separate studies were conducted as part ofphase 1 trials underan investigational new drug application to
Read more at: http://www.medicalnewstoday.com/releases/257250.php
